Ed Kuijper

microbiota studies, Cdiff, AMR and fungal infections.

[Jesus Rodriguez Baño @jesusrbano]

Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda: rapid assessment from the ESCMID Emerging Infections Subcommittee
@CMIJournal @ESCMID https://t.co/D7HVdj6omX

[Ed Kuijper @EdKuijper2]

@SmitsLab The role of the viriome in FMT: underestimated and understudied....

[Wiep Klaas Smits @SmitsLab]

Not just passengers: Phages as agents of genetic exchange in fecal microbiota transplantation https://t.co/EhJSgBDcN1

[Ed Kuijper @EdKuijper2]

Andes hantavirus outbreak on a cruise ship - an ESCMID Emerging Infections Subcommittee (EIS) rapid assessment - Clinical Microbiology and Infection https://t.co/dVjnexNRhu

[Wiep Klaas Smits @SmitsLab]

New bookchapter published! The book Clostridioides difficile has a chapter on Nanoluciferase use by Jeroen Corver, Ana Paiva and myself: https://t.co/UuK1HaijT6 Also check out the contributions of all the other experts in this volume!

[Wiep Klaas Smits @SmitsLab]

Paper 🚨: in this Narrative Review we describe the challenges and opportunity of a microbiome research facility, based on our experiences at @LUMC_Leiden with Center for Microbiome Analyses and Therapeutics (CMAT) #ESGHAMI @ESCMID @CMIJournal @EdKuijper2 https://t.co/o3fyqjHlCA

[Wiep Klaas Smits @SmitsLab]

🚨Publication alert! In this manuscript we describe the characterization of the non-toxigenic C. difficile (#NTCD) strain L-NTCD03 that we have used in our controlled human colonization experiments. https://t.co/eFV127Lala

[Wiep Klaas Smits @SmitsLab]

📢Publication alert: Clinical prevalence of collateral sensitivity: a systematic exploration of multicentre antimicrobial surveillance data 💊wonderful work from Coen van Hasselt's lab, with a minor contribution from yours truly - https://t.co/8rQUtpjJbI

[Ed Kuijper @EdKuijper2]

https://t.co/szbJt5Huzn
Review of our experiences in the past 6 years to establish a Microbiota Center in an academic setting with many stakeholders and an excellent research group of George Zeller. @SmitsLab @NicolasBenech2 @CMIJournal @EurFmt

[Ed Kuijper @EdKuijper2]

Amazing data on the Cfr -mediated antibiotic resistance in Cdiff. Typical a One Heath resistance mechanism? Also found in LA-MRSA and VRE...

[Wiep Klaas Smits @SmitsLab]

Epidemiology suggests that cfr(B) is associated with PhLOPSa resistance in C. difficile, but is this causative? Yes it is. We show this in our most recent preprint: https://t.co/VFD8bFNvPq

[JAMA @JAMA_current]

Clostridioides difficile is a gram-positive spore-forming anaerobic bacterium that can produce toxins.

Learn more about the epidemiology, diagnosis, and treatment of recurrent C difficile infections in this JAMA Insights: https://t.co/oG50WEtwMS

[Wiep Klaas Smits @SmitsLab]

As 2025 comes to an end, it is time to reflect on an exceptionally productive scientific year (22 manuscripts so far). I am grateful for these interactions, proud of the work, and looking forward to more exciting science with my team in 2026! https://t.co/pI7fSdATy8

[Ben Mullish @bhmullish]

Donor screening for #FMT gets ever more complicated, but is there rationale for this? Great to play a part in this critical appraisal and international Delphi process on this issue, now out in @Gut_BMJ: https://t.co/v2S9Op3Nvf @EdKuijper2 @IHepatology @ImperialMDR @EurFmt

[Ed Kuijper @EdKuijper2]

Excellent news from Gut....our article "Towards Optimising and Standardising Donor Screening for Faecal Microbiota Transplantation" has been accepted. International collaboration with FMT experts, completed with a Delphi-survey. More news in the following weeks.

[Ed Kuijper @EdKuijper2]

About ibezopolstat and Cdiff.....@SmitsLab @jvanprehn #cdiff

[Wiep Klaas Smits @SmitsLab]

🚨Publication alert! Stoked to report the structural basis for activity of a novel class of antimicrobials targeting Gram positive priority pathogens in @NatureComms. There is something for everyone on this paper; highlights 👇 1/9 https://t.co/InRfzj1GdJ

[Ed Kuijper @EdKuijper2]

Practical information for genereal physicians;
Recurrent Clostridioides difficile Infections https://t.co/etPGIFec1C
@SmitsLab @CdiffSupport @jvanprehn @marcellakrutova

[Ed Kuijper @EdKuijper2]

Nat Com 2025: https://t.co/NR0WBzd2Te
New glycopeptide EVG7 with excellent activity against C. difficile in mouse model. Excellent collaboration of Leiden with College of Veterinary Medicine, NC State University, US.

[Harry Sokol @h_sokol]

Join us !
Open #Postdoc position in my lab (Paris, France), to work on the Role of the Gut #microbiota in Host Cells Energy Metabolism in Health and #IBD
see details here
🔽🔽🔽🔽
https://t.co/nUv6slIV6k

please RT

[Ed Kuijper @EdKuijper2]

An important call is emerging from scientists, physicians, and patients to add C. difficile to the WHO priority list.....@ECDC_EU @rivm @NVMM_NL @EurFmt

https://t.co/vva13SM0Rj

[Ed Kuijper @EdKuijper2]

Finally completed, with our Serbian collegues!

Emerging Clostridioides difficile strains belonging to PCR ribotype 955 in Serbia are distinct from metronidazole resistant RT955 outbreak isolates from the UK https://t.co/KqMjqozAHb